Follow Us

       


"Like" us on Facebook

Clinical Trials

Cancer - Breast Cancer

Title Start Date Status
ACR BI-RADS Category 3 or 4
  Open to Enrollment
Breast Cancer - Novartis (TRIO)
  Open to Enrollment
DCIS, HER2 Positive
  Open to Enrollment
HER2 Positive, Metastatic with CNS progression after Trastuzumab
  Open to Enrollment

Cancer - GE & Stomach Cancer

Title Start Date Status
GE & Stomach Cancer - MM-111-13-02-04/Merrimack
  Open to Enrollment

Cancer - Hodgkin Lymphoma

Title Start Date Status
Front line advanced
  Open to Enrollment

Cancer - Lung Cancer

Title Start Date Status
NSCLC (Stage IIIB/IV) 2nd Line
  Open to Enrollment
NSCLC diagnosis
  Open to Enrollment

Cancer - Melanoma

Title Start Date Status
BRAF+, Adjuvant
  Open to Enrollment

Cancer - Multiple Myeloma

Title Start Date Status
Newly Diagnosed
  Open to Enrollment
Refractory to Lenalidomide
  Open to Enrollment
Relapsing or progressive disease. Following 1-3 prior regimens
  Open to Enrollment

Cancer - Non-Hodgkin Lymphoma

Title Start Date Status
Previously treated Indolent NHL
  Open to Enrollment
Previously treated Indolent NHL
  Open to Enrollment

Cancer - Prostate Cancer

Title Start Date Status
Castration and Taxane resistant
  Open to Enrollment
Failed all other available Treatment
  Open to Enrollment

This is the fat footer - edit page 906 to add content.